Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., Commvault Systems, Inc., ICU Medical, Inc., Incyte Corporation, MOCON, Inc., Ocwen Financial Corporation and ThereapeuticsMD, Inc.

TXMD, CVLT, ICUI, INCY, ONIT

PR Newswire

NEW YORK, April 28, 2017 /PRNewswire/ --

Amyris, Inc. (AMRS)

Lifshitz & Miller announces investigation on behalf of AMRS investors after AMRS reported a $10 million decrease in revenue from March 2, 2017 to April 3, 2017 attributed to AMRS' decision to take an equity stake in one of Blue California's affiliates instead of taking a cash payment as required under the license agreement.

If you are an AMRS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Commvault Systems, Inc. (CVLT)

Lifshitz & Miller announces investigation on behalf of CVLT investors concerning whether CVLT misrepresented forecasts of future results since at least 2013.

If you are a CVLT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ICU Medical, Inc. (ICUI)

Lifshitz & Miller announces investigation on behalf of ICUI investors after ICUI revealed it received a subpoena from the U.S. Department of Justice for documents about manufacturing, selling, pricing and shortages of intravenous solutions ICUI gained when it acquired the infusion systems business of Pfizer Inc.'s Hospira unit.

If you are an ICUI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Incyte Corporation (INCY)

Lifshitz & Miller announces investigation on behalf of INCY investors after the FDA rejected INCY's New Drug Application for baricitinib citing the need for additional data to characterize safety concerns.

If you are an INCY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

MOCON, Inc. (MOCO)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed sale of MOCO to AMETEK, Inc. for $30.00 in cash per share.

If you are a MOCO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Ocwen Financial Corporation (OCN)

Lifshitz & Miller announces investigation on behalf of OCN investors concerning whether OCN made widespread accounting and financial errors in borrowers' accounts and carried out illegal foreclosures. 

If you are an OCN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

TherapeuticsMD, Inc. (TXMD)

Lifshitz & Miller announces investigation on behalf of TXMD investors concerning whether TXMD's New Drug Application for TX-004HR was deficient and not supported by complete clinical data, resulting in a potential delay in being approved by the United States Food and Drug Administration.

If you are a TXMD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ATTORNEY ADVERTISING. © 2017 Lifshitz & Miller LLP.  The law firm responsible for this advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz & Miller LLP
Phone:  516-493-9780 
Facsimile: 516-280-7376
Email: info@jlclasslaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lifshitz--miller-llp-announces-investigation-of-amyris-inc-commvault-systems-inc-icu-medical-inc-incyte-corporation-mocon-inc-ocwen-financial-corporation-and-thereapeuticsmd-inc-300448276.html

SOURCE Lifshitz & Miller Law Firm



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today